Wellington Management Group LLP Sells 159,258 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH)

Wellington Management Group LLP lessened its stake in Theravance Biopharma, Inc. (NASDAQ:TBPH) by 45.4% during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 191,329 shares of the biopharmaceutical company’s stock after selling 159,258 shares during the quarter. Wellington Management Group LLP’s holdings in Theravance Biopharma were worth $1,542,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. Dimensional Fund Advisors LP raised its holdings in shares of Theravance Biopharma by 38.4% during the 2nd quarter. Dimensional Fund Advisors LP now owns 330,181 shares of the biopharmaceutical company’s stock worth $2,800,000 after acquiring an additional 91,679 shares in the last quarter. BNP Paribas Financial Markets increased its holdings in shares of Theravance Biopharma by 88.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 305,480 shares of the biopharmaceutical company’s stock worth $2,462,000 after buying an additional 143,781 shares during the last quarter. Marshall Wace LLP raised its position in shares of Theravance Biopharma by 83.6% during the 2nd quarter. Marshall Wace LLP now owns 297,499 shares of the biopharmaceutical company’s stock valued at $2,523,000 after buying an additional 135,426 shares in the last quarter. GSA Capital Partners LLP lifted its holdings in shares of Theravance Biopharma by 12.6% in the 3rd quarter. GSA Capital Partners LLP now owns 229,780 shares of the biopharmaceutical company’s stock valued at $1,852,000 after acquiring an additional 25,691 shares during the last quarter. Finally, Bank of Montreal Can grew its position in Theravance Biopharma by 141.0% in the second quarter. Bank of Montreal Can now owns 160,138 shares of the biopharmaceutical company’s stock worth $1,414,000 after acquiring an additional 93,702 shares in the last quarter. Institutional investors own 99.10% of the company’s stock.

Insider Transactions at Theravance Biopharma

In other Theravance Biopharma news, SVP Rhonda Farnum sold 4,000 shares of Theravance Biopharma stock in a transaction on Monday, November 11th. The stock was sold at an average price of $9.00, for a total transaction of $36,000.00. Following the completion of the sale, the senior vice president now directly owns 322,743 shares of the company’s stock, valued at $2,904,687. The trade was a 1.22 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 6.90% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $15.00 price objective on shares of Theravance Biopharma in a research note on Monday, September 16th. Four analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $13.75.

Theravance Biopharma Price Performance

Theravance Biopharma stock opened at $9.71 on Thursday. The firm has a market capitalization of $477.48 million, a P/E ratio of -9.61 and a beta of 0.23. Theravance Biopharma, Inc. has a 1-year low of $7.44 and a 1-year high of $11.71. The company’s 50-day moving average is $9.16 and its 200 day moving average is $8.80.

Theravance Biopharma (NASDAQ:TBPH) last released its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.16). The business had revenue of $16.87 million during the quarter, compared to analysts’ expectations of $16.11 million. Theravance Biopharma had a negative return on equity of 24.79% and a negative net margin of 78.18%. During the same quarter in the previous year, the business earned ($0.17) EPS. Research analysts anticipate that Theravance Biopharma, Inc. will post -1.09 earnings per share for the current fiscal year.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.